ReviewBiotechnology advances
Plasmid DNA vaccine vector design: impact on efficacy, safety and upstream production.
Review in Biotechnology advances. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 66 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
66 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Independent validation of induced overexpression efficiency across 242 experiments shows a success rate of 39.Scientific reports · 2019Pooled it
- Review
- DNA and mRNA Vaccines Against Hantaviruses: Antigen Design, Delivery Strategies and Translational Progress.Molecules (Basel, Switzerland) · 2026Review
- Pre-Clinical Development of Two DNA Vaccines Encoding MrkA of Klebsiella pneumoniae: Effect of Plasmid Backbone on Immunogenicity and Protective Efficacy Against Sepsis.Microbial biotechnology · 2026Article
- Backbone-Minimised Nanoplasmid DNA Systems Enable High-Titre AAV Production in Suspension HEK293 Platforms.Pharmaceutics · 2026Article
- When RNA goes off script: ensuring transcript fidelity in transgene expression.The EMBO journal · 2026Review
- Inducible genome-wide mutagenesis for improvement of pDNA production by E. coli.Microbial cell factories · 2025Article
- From genetic code to global health: the impact of nucleic acid vaccines on disease prevention and treatment.RSC medicinal chemistry · 2025Review
- Live Attenuated Bacterial Vectors as Vehicles for DNA Vaccine Delivery: A Mini Review.The Malaysian journal of medical sciences : MJMS · 2024Review
- Delivery of DNA-Based Therapeutics for Treatment of Chronic Diseases.Pharmaceutics · 2024Review
- Designing of a multi-epitopes based vaccine againstFrontiers in immunology · 2024Article
- Sulfate limitation increases specific plasmid DNA yield and productivity in E. coli fed-batch processes.Microbial cell factories · 2023Article
- Exploring the Potential of a Genome-ReducedInternational journal of molecular sciences · 2023Article
- Multiplexed long-read plasmid validation and analysis using OnRamp.Genome research · 2023Article
- Developments in Rabies Vaccines: The Path Traversed from Pasteur to the Modern Era of Immunization.Vaccines · 2023Review
- Defining the Emergence of New Immunotherapy Approaches in Breast Cancer: Role of Myeloid-Derived Suppressor Cells.International journal of molecular sciences · 2023Review
- Article
- LAMP1 targeting of the large T antigen of Merkel cell polyomavirus results in potent CD4 T cell responses and tumor inhibition.Frontiers in immunology · 2023Article
- Multiple-Gene Regulation for Enhanced Antitumor Efficacy with Branch-PCR-Assembled TP53 and MYC Gene Nanovector.Molecules (Basel, Switzerland) · 2022Article
- Nucleic Acid Delivery from Granular Hydrogels.Advanced healthcare materials · 2022Article
6 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Critical molecular and cellular biological factors impacting design of licensable DNA vaccine vectors that combine high yield and integrity during bacterial production with increased expression in mammalian cells are reviewed. Food and Drug Administration (FDA), World Health Organization (WHO) and European Medical Agencies (EMEA) regulatory guidance's are discussed, as they relate to vector design and plasmid fermentation. While all new vectors will require extensive preclinical testing to validate safety and performance prior to clinical use, regulatory testing burden for follow-on products can be reduced by combining carefully designed synthetic genes with existing validated vector backbones. A flowchart for creation of new synthetic genes, combining rationale design with bioinformatics, is presented. The biology of plasmid replication is reviewed, and process engineering strategies that reduce metabolic burden discussed. Utilizing recently developed low metabolic burden seed stock and fermentation strategies, optimized vectors can now be manufactured in high yields exceeding 2 g/L, with specific plasmid yields of 5% total dry cell weight.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.